Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Efficacy and Safety of Gynomax® XL Ovule (Gyno-Türk)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03839875
Recruitment Status : Completed
First Posted : February 15, 2019
Last Update Posted : January 31, 2020
Sponsor:
Collaborator:
Monitor CRO
Information provided by (Responsible Party):
Exeltis Turkey

Brief Summary:
Efficacy and safety of Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections will be evaluated in this open label, single-arm, multicentral study.

Condition or disease Intervention/treatment Phase
Trichomonal Vaginitis Bacterial Vaginosis Candidal Vulvovaginitis Mixed Vaginal Infections Drug: Gynomax® XL Vaginal Ovule Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections
Actual Study Start Date : April 3, 2019
Actual Primary Completion Date : August 9, 2019
Actual Study Completion Date : August 9, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Active Treatment Drug: Gynomax® XL Vaginal Ovule
tioconazole, tinidazole, lidocaine




Primary Outcome Measures :
  1. Percentage of patients with complete response to treatment [ Time Frame: 10 Days after completion of treatment ]

Secondary Outcome Measures :
  1. Percentage of patients with partial response to treatment [ Time Frame: 10 Days after completion of treatment ]
  2. Percentage of patients with no response to treatment [ Time Frame: 10 Days after completion of treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patients with age ≥ 18 and ≤ 45 years
  • Patients requiring treatment for bacterial vaginosis, candidal vulvovaginitis or mixed infections according to the investigator's decision
  • Signed informed consent

Exclusion Criteria:

  • Known hypersensitivity to active ingredients of the study medications
  • Vaginismus, endometriosis, dyspareunia
  • Detection of urinary tract infection in urinalysis
  • Acute or chronic infections such as pancreatitis, hypertriglyceridemia, liver diseases, benign or malign tumors
  • Usage of herbal medicines that interfere with microsomal enzymes, especially cytochrome P450 (phenytoin, phenobarbital, primidone, carbamazepine, rifampicin, topiramate, felbamate, griseofulvin, HIV protease inhibitors such as ritonavir, nucleoside reverse transcriptase inhibitors such as efavirenz)
  • History of cardiovascular event
  • Advanced hypertension and diabetes
  • Presence or known risk or of venous or arterial thromboembolism
  • Undiagnosed abnormal vaginal bleeding, bleeding disorders, genital tumors
  • Use of drugs containing ombitasvir / paritaprevir / ritonavir or dasabuvir during or two weeks before initiation of the study
  • Pregnancy and/or breastfeeding
  • Participation in any other trial 30 days before initiation of the study
  • Postmenopausal women
  • Abuse of alcohol
  • Usage of medications containing acenocoumarol, anisindione, dicoumarol, phenindione, phenprocoumon, warfarin, cholestyramine, cimetidine, cyclosporine, disulfiram, fluorouracil, fosphenitoin, ketoconazole, lithium, rifampin, tacrolimus or propranolol
  • Presence of a sexually transmitted disease such as syphilis, gonorrhea, etc. according to the investigators decision

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03839875


Locations
Layout table for location information
Turkey
Ege University Family Planning and Infertility Application and Research Centeraştırma Merkezi
İzmir, Turkey, 35100
Sponsors and Collaborators
Exeltis Turkey
Monitor CRO
Layout table for additonal information
Responsible Party: Exeltis Turkey
ClinicalTrials.gov Identifier: NCT03839875    
Other Study ID Numbers: MON564.130.1
First Posted: February 15, 2019    Key Record Dates
Last Update Posted: January 31, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Vaginosis, Bacterial
Candidiasis, Vulvovaginal
Trichomonas Vaginitis
Vaginal Diseases
Vaginitis
Vulvovaginitis
Genital Diseases, Female
Bacterial Infections
Vulvitis
Vulvar Diseases
Candidiasis
Mycoses
Trichomonas Infections
Protozoan Infections
Parasitic Diseases